Cargando…
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
INTRODUCTION: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study. METHODS: Baseline CD30...
Autores principales: | Kim, Youn H., Prince, H. Miles, Whittaker, Sean, Horwitz, Steven M., Duvic, Madeleine, Bechter, Oliver, Sanches, Jose A., Stadler, Rudolf, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Eradat, Herbert, Pinter-Brown, Lauren C., Ortiz-Romero, Pablo L., Akilov, Oleg E., Trotman, Judith, Taylor, Kerry, Weichenthal, Michael, Walewski, Jan, Fisher, David, McNeeley, Marise, Gru, Alejandro A., Brown, Lisa, Palanca-Wessels, M. Corinna, Lisano, Julie, Onsum, Matthew, Bunn, Veronica, Little, Meredith, Trepicchio, William L., Dummer, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347228/ https://www.ncbi.nlm.nih.gov/pubmed/33794441 http://dx.doi.org/10.1016/j.ejca.2021.01.054 |
Ejemplares similares
-
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
por: Horwitz, Steven M., et al.
Publicado: (2021) -
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022) -
Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018) -
Brentuximab Vedotin
Publicado: (2012) -
Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)